2. Search Result
Search Result
Results for "

ATP inhibitor

" in MedChemExpress (MCE) Product Catalog:

1336

Inhibitors & Agonists

5

Screening Libraries

13

Fluorescent Dyes

17

Biochemical Assay Reagents

9

Peptides

3

Inhibitory Antibodies

100

Natural
Products

55

Isotope-Labeled Compounds

1

Antibodies

5

Click Chemistry

5

Oligonucleotides

11

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16450
    SB 204990
    20+ Cited Publications

    		 ATP Citrate Lyase Metabolic Disease
    SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
    SB 204990
  • HY-119374
    BRM/BRG1 ATP Inhibitor-1
    35+ Cited Publications

    		 Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity .
    BRM/BRG1 ATP Inhibitor-1
  • HY-10992
    AZD-7762
    20+ Cited Publications

    		 Checkpoint Kinase (Chk) Cancer
    AZD-7762 is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC50 of 5 nM for Chk1.
    AZD-7762
  • HY-16107
    BMS-303141
    20+ Cited Publications

    		 ATP Citrate Lyase Metabolic Disease
    BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
    BMS-303141
  • HY-15247
    Vistusertib
    30+ Cited Publications

    AZD2014

    		 mTOR Autophagy Apoptosis Cancer
    Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
    Vistusertib
  • HY-101053
    Src Inhibitor 1
    15+ Cited Publications

    Src Kinase inhibitor 1; Src-l1

    		 Src Cancer
    Src Inhibitor 1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.
    Src Inhibitor 1
  • HY-125017
    Bozitinib
    1 Publications Verification

    PLB-1001; CBT-101; Vebreltinib

    		 c-Met/HGFR Cancer
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
    Bozitinib
  • HY-11092
    BMS-509744
    5 Publications Verification

    		 Itk Inflammation/Immunology
    BMS-509744 is a potent, selective and ATP competitive Itk inhibitor with an IC50 of 19 nM.
    BMS-509744
  • HY-15512
    OTSSP167
    20+ Cited Publications

    OTS167

    		 MELK Cancer
    OTSSP167 (OTS167) is a highly potent and ATP-competitive MELK inhibitor with IC50 value of 0.41 nM.
    OTSSP167
  • HY-15513
    TC-DAPK 6
    10+ Cited Publications

    		 DAPK Cancer
    TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
    TC-DAPK 6
  • HY-15512A
    OTSSP167 hydrochloride
    20+ Cited Publications

    OTS167 hydrochloride

    		 MELK Cancer
    OTSSP167 (OTS167) hydrochloride is a highly potent and ATP-competitive MELK inhibitor with IC50 value of 0.41 nM.
    OTSSP167 hydrochloride
  • HY-111651
    Gboxin
    4 Publications Verification

    		 Oxidative Phosphorylation ATP Synthase Mitochondrial Metabolism Cancer
    Gboxin is an oxidative phosphorylation (OXPHOS) inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity .
    Gboxin
  • HY-17537
    APY29
    10+ Cited Publications

    		 IRE1 Cancer
    APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .
    APY29
  • HY-136532
    ZT-1a
    3 Publications Verification

    		 NKCC Neurological Disease
    ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC50s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively .
    ZT-1a
  • HY-12382
    NMS-P715

    		Mps1 Cancer
    NMS-P715 is a selective, ATP-competitive inhibitor of MPS1, with an IC50 of 182 nM.
    NMS-P715
  • HY-133117
    BAY-985
    4 Publications Verification

    		 IKK Cancer
    BAY-985, a chemical probe, is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy .
    BAY-985
  • HY-148394
    UCK2 Inhibitor-1
    2 Publications Verification

    		 DNA/RNA Synthesis Cancer
    UCK2 Inhibitor-1 (Compound 20874830-2) is a non-competitive UCK2 inhibitor with an IC50 of 4.7 μM. UCK2 Inhibitor-1 acts as a non-competitive inhibitor against uridine and ATP, and functionally inhibits the enzymatic activity of UCK2. UCK2 Inhibitor-1 suppresses the uridine salvage pathway. UCK2 Inhibitor-1 can be used in chronic myeloid leukemia research .
    UCK2 Inhibitor-1
  • HY-12660
    MPI-0479605
    5+ Cited Publications

    		 Mps1 Apoptosis Cancer
    MPI-0479605 is a potent and selective ATP-competitive inhibitor of Mps1, with an IC50 of 1.8 nM.
    MPI-0479605
  • HY-P2657
    Verucopeptin

    		HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite Cancer
    Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.
    Verucopeptin
  • HY-137888A
    Oxidized ATP trisodium salt

    oATP trisodium salt

    		 P2X Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. Oxidized ATP trisodium salt irreversibly antagonizes P2X7R activation. Oxidized ATP trisodium salt inhibits c-reactive protein (CRP)-induced NLRP3 inflammasome activation. Oxidized ATP trisodium salt can be used for research of atherosclerosis .
    Oxidized ATP trisodium salt
  • HY-12062
    PD318088
    1 Publications Verification

    		 MEK Cancer
    PD318088 is a potent, allosteric and non-ATP competitive MEK1/2 inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .
    PD318088
  • HY-16902
    RO9021

    		Syk Inflammation/Immunology
    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
    RO9021
  • HY-112914
    mTOR inhibitor-1
    3 Publications Verification

    		 mTOR Autophagy Cancer
    mTOR inhibitor-1 (Compound C-4) is an ATP-Competitive mTOR inhibitor which can suppress cells proliferation and inducing autophagy .
    mTOR inhibitor-1
  • HY-114858
    Epiblastin A
    1 Publications Verification

    		 Casein Kinase Cancer
    Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC50s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1 .
    Epiblastin A
  • HY-145940
    BAY-204

    BRD3727

    		 Casein Kinase Cancer
    BAY-204 (BRD3727) is a potent, ATP-competitive, and selective CSNK1α inhibitor (IC50 = 2 nM at 10 μM ATP; 12 nM at 1 mM ATP). BAY-204 can be used for the study of acute myeloid leukemia (AML) .
    BAY-204
  • HY-108605
    PIM1-IN-2

    		Pim Cancer
    PIM1-IN-2 is a potent and ATP competitive Pim-1 inhibitor with a Ki of 91 nM. PIM1-IN-2 targets the ATP-binding kinase hinge region not by forming classical hydrogen bonds .
    PIM1-IN-2
  • HY-108667
    TNP-ATP triethylammonium

    		P2X Receptor Interleukin Related Fluorescent Dye Neurological Disease
    TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .
    TNP-ATP triethylammonium
  • HY-145946
    BRM/BRG1 ATP Inhibitor-2

    		Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor for the research of BAF-related disorders.
    BRM/BRG1 ATP Inhibitor-2
  • HY-118960
    BMS-199264 hydrochloride

    		ATP Synthase Cardiovascular Disease
    BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
    BMS-199264 hydrochloride
  • HY-50948
    Bay 65-1942 hydrochloride
    4 Publications Verification

    		 IKK Inflammation/Immunology
    Bay 65-1942 hydrochloride is an ATP-competitive and selective IKKβ inhibitor.
    Bay 65-1942 hydrochloride
  • HY-135893
    SGK1-IN-2

    		SGK Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    SGK1-IN-2 (Compound 14h) is a selective, ATP-competitive SGK1 inhibitor, with an IC50 of 0.005 μM at 10 μM ATP and an IC50 of 0.025 μM at 500 μM ATP. SGK1-IN-2 can be used in studies of cancer, hypertension and diabetes .
    SGK1-IN-2
  • HY-P1292
    PKG inhibitor peptide
    2 Publications Verification

    		 PKG Cancer
    PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM .
    PKG inhibitor peptide
  • HY-115743
    TAK1-IN-3

    		MAP3K Cancer
    TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
    TAK1-IN-3
  • HY-101523
    Cdc7-IN-1
    1 Publications Verification

    		 CDK Cancer
    Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death .
    Cdc7-IN-1
  • HY-16982
    Cercosporamide

    (-)-Cercosporamide

    		 Fungal MNK PKC Infection Cancer
    Cercosporamide is a highly potent, ATP-competitive PKC kinase inhibitor targeting to PKC1, with an IC50 of <50 nM and a Ki of <7 nM. Cercosporamide is a unique Mnk inhibitor.
    Cercosporamide
  • HY-10992A
    AZD-7762 hydrochloride
    20+ Cited Publications

    		 Checkpoint Kinase (Chk) Cancer
    AZD-7762 hydrochloride is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC50 of 5 nM for Chk1.
    AZD-7762 hydrochloride
  • HY-112355
    Aurora kinase inhibitor-2

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
    Aurora kinase inhibitor-2
  • HY-P11005
    P259

    		Dynamin ATP Synthase Neurological Disease
    P259 is a Drp1-Mff inhibitor. P259 distinguishes physiological from pathological fission by specifically inhibiting Drp1-Mff interaction. P259 elongates cell mitochondria and disrupts mitochondrial function and motility. P259 reduces ATP levels and alters mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a short lifespan in Huntington's disease (HD) mice model .
    P259
  • HY-14256
    BMS-191095
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease Neurological Disease
    BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .
    BMS-191095
  • HY-112468
    PNU112455A hydrochloride

    		CDK Cancer
    PNU112455A hydrochloride is an ATP-competitive CDK2 and CDK5 inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively .
    PNU112455A hydrochloride
  • HY-19966
    K858 (Racemic)
    1 Publications Verification

    		 Kinesin Apoptosis Cancer
    K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.
    K858 (Racemic)
  • HY-14715
    CCT241533

    		Checkpoint Kinase (Chk) Cancer
    CCT241533 is a potent and selective ATP competitive inhibitor of CHK2 with an IC50 of 3 nM and Ki of 1.16 nM .
    CCT241533
  • HY-137325A
    2-Chloro-ATP sodium

    		Calcium Channel Metabolic Disease
    2-Chloro-ATP sodium (2-Chloro ATP) is an adenine nucleotide and an analog of ATP. It is an antagonist of the purinergic P2Y1 receptor and inhibits intracellular calcium mobilization induced by ADP (HY-W010918) in Jurkat cells expressing the human receptor (Ki=2.3 μM). 2-Chloro-ATP sodium is an agonist of the purinergic P2X receptor and induces inward currents in HEK293 cells expressing human bladder smooth muscle or rat PC12 forms of the receptor (EC50=0.5 and 2.5 μM). 2-Chloro-ATP sodium induces relaxation of precontracted guinea pig cecal strips in a concentration-dependent manner. 2-Chloro-ATP sodium has been used to study the substrate specificity of cyclic nucleotide-dependent protein kinases such as protein kinase A (PKA) and PKG.
    2-Chloro-ATP sodium
  • HY-112715
    ATP synthase inhibitor 1

    		ATP Synthase Cardiovascular Disease
    ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
    ATP synthase inhibitor 1
  • HY-125147
    A-1293201

    		NAMPT Cancer
    A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD +/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .
    A-1293201
  • HY-131800
    3'-NH2-ATP

    		ATP Synthase Metabolic Disease
    3'-NH2-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a Ki of 2.3 μM. 3'-NH2-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C .
    3'-NH2-ATP
  • HY-115741
    3BrB-PP1

    		Nucleoside Antimetabolite/Analog Neurological Disease Cancer
    3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket) .
    3BrB-PP1
  • HY-112392
    GSK-3 Inhibitor XIII

    		GSK-3 Cancer
    GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM .
    GSK-3 Inhibitor XIII
  • HY-148374
    BRM/BRG1 ATP Inhibitor-4

    		Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-4 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-4 can be used for the research of cancers and BAF complex-related disorders .
    BRM/BRG1 ATP Inhibitor-4
  • HY-161681
    Formycin triphosphate

    		Guanylate Cyclase Metabolic Disease
    Formycin triphosphate is a fluorescent analogue of ATP which on binding to enzyme active sites exhibits enhanced fluorescence. Formycin triphosphate is an ATP-competitive chicken liver pyruvate carboxylase inhibitor. Formycin triphosphate potentiates atrial natriuretic factor (ANF)-stimulated guanylate cyclase activity with an EC50 at about 90 μM and inhibits ATP-stimulated guanylate cyclase activity with an IC50 at about 100 μM .
    Formycin triphosphate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: